This invention relates to a novel use of compounds which are angiotensin ii receptor agonists (ang ii), more particularly, ang ii type 2 receptor agonists (the at2 receptor), and especially agonists that selectively bind to at2 receptor for therapeutic treatment of pulmonary fibrosis, in particular idiopathic pulmonary fibrosis.esta invenção se refere a um novo uso de compostos que são agonistas de receptor de angiotensina ii (ang ii), mais particularmente, agonistas do receptor de ang ii tipo 2 (o receptor at2), e, especialmente, agonistas que se ligam seletivamente ao receptor at2, para tratamento terapêutico de fibrose pulmonar, em particular, fibrose pulmonar idiopática.
